Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases (NEUTROGENE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01952275 |
|
Recruitment Status
:
Recruiting
First Posted
: September 27, 2013
Last Update Posted
: September 27, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a discovery cohort formed based on the certainty of diagnosis. The DNA of patients in the discovery cohort is analyzed by whole exome sequencing which identifies all protein-coding genetic variants. Subsequently, statistical burden tests are going to identify enrichment of rare coding genetic variants in patients affected by Neutrophil-Mediated Inflammatory Skin Diseases.
The ultimate goal is to reveal the responsible gene(s) that may then be targets for clinical intervention.
| Condition or disease | Intervention/treatment |
|---|---|
| Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue Pyoderma Gangrenosum Erosive Pustular Dermatosis of the Scalp Sweet's Syndrome Behcet's Disease Bowel-associated Dermatosis-arthritis Syndrome Pustular Psoriasis Acute Generalized Exanthematous Pustulosis Keratoderma Blenorrhagicum Sneddon-Wilkinson Disease IgA Pemphigus Amicrobial Pustulosis of the Folds Infantile Acropustulosis Transient Neonatal Pustulosis Neutrophilic Eccrine Hidradenitis Rheumatoid Neutrophilic Dermatitis Neutrophilic Urticaria Still's Disease Erythema Marginatum Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes Dermatitis Herpetiformis Linear IgA Bullous Dermatosis Bullous Systemic Lupus Erythematosus Inflammatory Epidermolysis Bullosa Aquisita Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis) Small Vessel Vasculitis Including Urticarial Vasculitis Erythema Elevatum Diutinum Medium Vessel Vasculitis | Procedure: Collection of biological samples |
Timeframe:
- Collection of DNA for discovery cohort until 05/2016
- Data analysis until 12/2014 for pyoderma gangrenosum, until 12/2016 for other NMID
- Report and data presentation early 2015 for PG, 2017 for other NMID
| Study Type : | Observational |
| Estimated Enrollment : | 600 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Cross-Sectional |
| Official Title: | Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses |
| Study Start Date : | January 2014 |
| Estimated Primary Completion Date : | January 2020 |
| Estimated Study Completion Date : | January 2020 |
- Enrichment of rare coding genetic variants [ Time Frame: baseline ]Whole exome sequencing is going to detect rare coding genetic variants in cases of Neutrophil-Mediated Inflammatory Skin Diseases. Statistical burden tests are applied to test for excess of rare variants in cases versus available controls of matching ancestry.
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 120 Years (Child, Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Inclusion criteria:
- History of NMID or active disease.
- Informed consent.
Exclusion criteria:
- No consent to either part of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01952275
| Contact: Alexander Navarini, MD | alexander.navarini@usz.ch |
| Switzerland | |
| University Hospital Zurich, Dept. of Dermatology | Recruiting |
| Zurich, ZH, Switzerland, 8091 | |
| Principal Investigator: | Alexander Navarini, MD | University Hospital Zurich, Dept. of Dermatology |
| Responsible Party: | University of Zurich |
| ClinicalTrials.gov Identifier: | NCT01952275 History of Changes |
| Other Study ID Numbers: |
USZ-DER-AAN-019 |
| First Posted: | September 27, 2013 Key Record Dates |
| Last Update Posted: | September 27, 2016 |
| Last Verified: | September 2016 |
Additional relevant MeSH terms:
|
Syndrome Psoriasis Dermatitis Lupus Erythematosus, Systemic Urticaria Vasculitis Epidermolysis Bullosa Erythema Hidradenitis Behcet Syndrome Pemphigus Pyoderma Skin Diseases Pyoderma Gangrenosum Familial Mediterranean Fever |
Dermatitis Herpetiformis Skin Diseases, Vesiculobullous Linear IgA Bullous Dermatosis Acute Generalized Exanthematous Pustulosis Sweet Syndrome Keratosis Epidermolysis Bullosa Acquisita Vasculitis, Leukocytoclastic, Cutaneous Disease Pathologic Processes Skin Diseases, Papulosquamous Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Skin Diseases, Vascular |